Amendments to the Claims

1-4. (Cancelled)

(Previously presented) The method of claim 6, wherein said antisense morpholino oligomer comprises phosphorodiamidate intersubunit linkages, joining a morpholino nitrogen of one morpholino subunit to a 5'-exocyclic carbon of an adjacent morpholino subunit.

(Currently amended) A method of promoting hematopoietic stem cell differentiation <u>in</u> <u>vitro</u>, the method comprising:

contacting hematopoietic stem cells in vitro with one or more an antisense morpholino which oligomer comprises oligomer[[s]] having a substantially uncharged backbone and the sequence presented as SEQ ID NO:1, and has a maximum Length of 40 nucleotides,

wherein said contacting results in a decrease in the number of high proliferative potential colony forming cells (HPP-CFC) relative to the number of clonogenic cells, as compared to stem cells not contacted with said oligomer.

AND which decrease in HPP-CFC is indicative of lematopoietic STEM cell differentiation

7-9. (Cancelled)

- 3 16. (Previously presented) The method of claim 6, wherein said hematopoietic stem cells are provided by:
 - (a) obtaining a stem cell-containing cell population from a subject; and
- (b) treating the cell population in manner effective to enrich the cell population for stem cells.

11-18. (Cancelled)

- (Previously presented) A composition comprising an antisense oligomer having an uncharged backbone, wherein said antisense oligomer is characterized by
 - (a) the ability to hybridize with the complementary sequence of a target RNA with high

affinity at a Tm greater than 50°C,

- (b) nuclease resistance, and
- (c) the capability for active or facilitated transport into cells;
 and has the sequence presented as SEQ ID NO:1. And has a maximum Length of 40

 NU CLEOTI Jes

20-21. (Cancelled)

backbone which is substantially uncharged, wherein said oligomer has the base sequence presented as SEQ ID NO:1. And has a maximum Length of 40 Nucleotides.